Manage episode 298283253 series 1076397
Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus, a global leader in influenza prevention, discusses data from a first-of-its-kind co-administration study conducted by Novavax of the SARS-CoV-2 vaccine candidate (Novavax, NVX-CoV2373) and an approved influenza vaccine (Seqirus, Flucelvax Quadrivalent and Fluad). He talks about the potential advantages for patients and physicians to co-administer an approved COVID-19 and influenza vaccine, how these findings may impact proposed immunization scheduling for varying age groups and alter CDC recommendations, and the importance of these findings as we approach a critical 2021/22 influenza season while many populations are still in need of a primary COVID-19 vaccine series or booster dose.
#COVID #Influenza #Seqirus
Dr. Gregg Sylvester serves as the Chief Medical Officer of Seqirus. He has been with the company since 2016, previously serving as Vice President of Medical Affairs. Prior to this, Dr. Sylvester held a variety of senior management positions, including Global Medical Lead for Pfizer’s pediatric pneumococcal vaccine and Worldwide Medical Lead for Merck’s HPV vaccine and Cabinet Secretary for Delaware’s Health & Social Services. Dr. Sylvester is a preventive medicine expert with a passion for disease prevention and health promotion on a local, statewide, and global basis. He has focused his career on developing sound health policy, implementing innovative public health programs and accelerating vaccine use worldwide.